InvestSMART

HeraMED Limited (ASX:HMD)

ALERT: Price-sensitive ASX Announcement for HMD
Current share price for HMD : $0.039 -0.006 (-13.33%)+
Announcement
Release
30 Apr 2026 2:12PM
Price at Release
$0.045
Full Release
download
Summary
HeraMED Limited, an innovative medical data and technology company, reported significant progress in its quarterly activities and cashflow report for the quarter ending 31 March 2026. The company is focused on the digital transformation of women's and maternity care, emphasizing the US market with key partnerships and direct sales strategies. The partnership with Philips and the pilot deployment with Lee Health are central, with efforts to expand operations across US health systems. HeraMED raised $3.2 million to support its US deployments, maintaining a strong balance sheet with $3.145 million in cash. The company also noted advancements in its HeraCARE platform, which has recorded over 200,000 maternal vital measurements, and continues to scale its operations and data-driven strategies. Financially, the quarter saw a net cash outflow from operations of $851,000, with a strategic focus on commercializing its medical technologies in the US market.
Key Points
  • HeraMED advances US commercial activities with Philips partnership and Lee Health pilot.
  • Raised $3.2 million to support US deployments.
  • Maintained a strong cash position with $3.145 million at the end of the quarter.
  • Net cash outflow from operations was $851,000.
  • HeraCARE platform continues to scale with over 200,000 maternal measurements recorded.
  • Focusing on commercializing medical technologies in the US.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.